Breast implants face limited U.S. growth

The market for breast implants is expected to grow modestly in the U.S. over the nest few years, but European sales won't climb much at all, Millennium Research Group concludes in a new report. Among the factors leading to only modest U.S. sales: A rigorous U.S. approval process and a duopoly between the two main competitors--Allergan ($AGN) and Mentor. The EU market for breast implants remains much smaller, Millennium notes, and dipped by more than 2% from 2010 to 2011, with further declines expected through 2016. Release

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.